top of page
The Professional Network for Healthcare Experts
Lilly to Acquire AtaiBeckley in Up to $3.8bn Deal to Expand into Psychedelic Depression Therapies
Acquisition gives Lilly late-stage psychedelic pipeline targeting treatment-resistant depression and major psychiatric disorders
nuaxia
Jul 163 min read
Draig Therapeutics Raises $65M to Advance AMPA Modulator DT-101 for Depression Treatment
Neuropsychiatric drug developer Draig Therapeutics has raised $65 million in an oversubscribed Series B financing round to accelerate development of its pipeline, led by its investigational depression therapy DT-101.
nuaxia
Jul 154 min read
FDA Clears Zeta Surgical’s AI-Powered Robotic TMS Navigation System for Treatment-Resistant Depression
Zeta Surgical’s robotic navigation platform uses AI and computer vision to improve precision and repeatability during transcranial magnetic stimulation procedures.
nuaxia
Jul 133 min read
bottom of page